The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...
At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...
What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results